Osiris gains $50M

Baltimore-based Osiris Therapeutics has pocketed $50 million from a Swiss investment firm. That's more than twice the $20 million the biotech had hoped to raise in the round. Zurich-based Friedli Corporate Finance, which is owned by Osiris' chairman of the board, led the round. Osiris has been hot on the trail of a new adult stem cell treatment to regenerate diseased or damaged tissue. It expects to have its first commercial offering in 2006.

- read this story from the Baltimore Sun

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.